A biomarker, primer probe combination and application thereof for detecting cervical cancer gene methylation
The methylation marker of cervical cancer specific genes in urine was detected by fluorescence quantitative PCR technology, and combined with the target region methylation sequence of DPP6, GHSR and ZIC1, solving the specificity and low sensitivity of cervical cancer screening in the prior art. The problem has achieved efficient and accurate diagnosis of cervical cancer.
Patent Information
- Application Number
- CN202411170319.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-26
AI Technical Summary
Existing cervical cancer screening methods such as cytology and HR-HPV detection have problems with low specificity and low sensitivity, resulting in excessive diagnosis and treatment and unnecessary colposcopy, and the inability to effectively screen cervical cancer and precancerous lesions. .
Fluorescence quantitative PCR technology was used to detect cervical cancer-specific gene methylation markers in urine, and the target region methylated nucleotide sequences of target genes DPP6, GHSR and ZIC1 were combined with corresponding primer probe combinations to establish PCR reactions. system to achieve the diagnosis of cervical cancer.
It improves the diagnostic sensitivity and specificity of cervical cancer and precancerous lesions, and provides a fast and objective detection method through gene methylation examination of urine specimens, reducing unnecessary diagnosis and treatment processes.
Smart Images

Figure CN118685528B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of cervical cancer detection technology, and in particular to a biomarker, primer-probe combination, and its application for detecting cervical cancer gene methylation. Specifically, it relates to a biomarker, primer-probe combination, and its application for detecting cervical cancer-specific gene methylation in urine using quantitative real-time PCR technology. Background Technology
[0002] The rapid development of genomic technologies and the Cancer Genome Atlas (TCGA) project have revealed the extensive and previously unforeseen complexity and heterogeneity of human cancers. In response to this heterogeneity, the concept of "precision medicine" has been proposed to address the complex genetic and epigenetic processes underlying somatic cell evolution into malignant tumors. Precision medicine integrates environmental, clinical, and molecular data to develop personalized treatment, prevention, early detection, and screening programs.
[0003] Current cervical screening commonly involves cytology or human papillomavirus (HR-HPV) testing, focusing on detecting abnormal cells and HR-HPV infection. Cytology, a morphological examination, observes whether exfoliated cervical cells are abnormal. However, its results are subject to subjective factors, leading to inconsistent outcomes, especially for high-grade squamous intraepithelial lesions (HSIL+). HR-HPV testing checks for viral infection of the cervix. Persistent HR-HPV infection is a major cause of cervical cancer, but the vast majority of HR-HPV infections clear spontaneously within two years. Having HR-HPV infection does not necessarily mean having cervical cancer or precancerous lesions. Therefore, HR-HPV testing has low specificity, leading to an increase in referrals for colposcopy. When a woman's cytology and HR-HPV tests are positive, the next step is colposcopy, in which most women undergo a biopsy. However, most biopsies are negative or show CIN1 lesions, which mostly revert to normal epithelium within 24 months, resulting in overdiagnosis. However, only a small percentage of HR-HPV infections are associated with the progression from low-grade squamous intraepithelial lesion (LSIL) to cervical intraepithelial neoplasia grade 3 (CIN3), and approximately 30% of CIN3 lesions progress to cervical cancer.
[0004] Cervical cancer cells and precancerous lesions may detach outside the cervix or into the vagina and be excreted in urine. Therefore, cervical cancer can be diagnosed by detecting cancer cells or their genetic material in urine. Quantitative real-time polymerase chain reaction (PCR) can automatically amplify a trace amount of initial genetic material to hundreds of millions of copies in a short time; by recording the intensity of the fluorescence signal, the initial copy number can be indirectly reflected. Summary of the Invention
[0005] This invention provides a method for detecting cervical cancer-specific gene methylation markers in urine using quantitative real-time PCR technology, thereby enabling the detection of cervical cancer.
[0006] This invention provides a biomarker for detecting cervical cancer gene methylation, wherein the biomarker comprises a methylated nucleotide sequence in at least one target region of the target gene DPP6, a methylated nucleotide sequence in one target region of the target gene GHSR, and a methylated nucleotide sequence in at least one target region of the target gene ZIC1; wherein:
[0007] The target region of the target gene DPP6 was selected from chr7:154001964-154002281 and / or chr7:153748407-153748744;
[0008] The target region of the target gene GHSR was selected from chr3:172165506-172165751;
[0009] The target region of the target gene ZIC1 was selected from chr3:147127500-147127769 and / or chr3:147127988-147128286.
[0010] This invention also provides a primer-probe combination for detecting cervical cancer gene methylation, comprising any combination of at least two nucleic acid sequences as shown in 1)-3) below:
[0011] 1) PCR primers and probes for detecting DPP6 gene methylation, including the front primer shown in SEQ ID NO.1, the back primer shown in SEQ ID NO.2, and the fluorescent probe shown in SEQ ID NO.3; or, PCR primers and probes for detecting DPP6 gene methylation, including the front primer shown in SEQ ID NO.4, the back primer shown in SEQ ID NO.5, and the fluorescent probe shown in SEQ ID NO.6;
[0012] 2) PCR primers and probes for detecting GHSR gene methylation, including the front primer as shown in SEQ ID NO.7, the back primer as shown in SEQ ID NO.8, and the fluorescent probe as shown in SEQ ID NO.9;
[0013] 3) PCR primers and probes for detecting ZIC1 gene methylation, including the front primer shown in SEQ ID NO.10, the back primer shown in SEQ ID NO.11, and the fluorescent probe shown in SEQ ID NO.12; or, PCR primers and probes for detecting ZIC1 gene methylation, including the front primer shown in SEQ ID NO.13, the back primer shown in SEQ ID NO.14, and the fluorescent probe shown in SEQ ID NO.15.
[0014] Furthermore, the present invention also provides the application of the primer-probe combination for diagnosing cervical cancer gene methylation as described above in the preparation of a cervical cancer detection kit.
[0015] Preferably, the sample to be tested in the test kit is a urine sample.
[0016] Preferably, when used for PCR reaction, probes of the target gene DPP6, the target gene GHSR, the target gene GYPC, and the internal reference gene are attached with different fluorescent groups to establish the first PCR reaction system;
[0017] A second PCR reaction system was established by attaching probes for the target gene PAX1, the target gene ZIC1, and the internal reference gene with different fluorescent groups.
[0018] More preferably, when used in PCR reactions, the first PCR reaction system is set up as follows:
[0019] Add 2.5 μL to the 10×PCR reaction mix, 0.2-0.5 μL to the DPP6_1 front primer, 0.2-0.5 μL to the DPP6_1 back primer, 0.2-0.5 μL to the DPP6_1 probe, 0.2-0.5 μL to the DPP6_2 front primer, 0.2-0.5 μL to the DPP6_2 back primer, 0.2-0.5 μL to the DPP6_2 probe, and 0.2-0.5 μL to the GHSR front primer and the GHSR back primer. Add 0.2-0.5 μL of GHSR probe, 0.2-0.5 μL of GYPC pre-primer, 0.2-0.5 μL of GYPC post-primer, 0.2-0.5 μL of GYPC probe, 0.2-0.5 μL of GAPDH pre-primer, 0.2-0.5 μL of GAPDH post-primer, 0.2-0.5 μL of GAPDH probe, and 2 μL of B-DNA. Add double-distilled water to a total volume of 25 μL.
[0020] More preferably, when used in a PCR reaction, the second PCR reaction system is set up as follows:
[0021] For the 10×PCR reaction, add 2.5 μL of MIX, 0.2-0.5 μL of PAX1 pre-primer, 0.2-0.5 μL of PAX1 post-primer, 0.2-0.5 μL of PAX1 probe, 0.2-0.5 μL of ZIC1_1 pre-primer, 0.2-0.5 μL of ZIC1_1 post-primer, 0.2-0.5 μL of ZIC1_1 probe, 0.2-0.5 μL of ZIC1_2 pre-primer, 0.2-0.5 μL of ZIC1_2 post-primer, 0.2-0.5 μL of ZIC1_2 probe, 0.2-0.5 μL of GAPDH pre-primer, 0.2-0.5 μL of GAPDH post-primer, 0.2-0.5 μL of GAPDH probe, and 2 μL of B-DNA. Add double-distilled water to a total volume of 25 μL.
[0022] Compared with the prior art, the present invention has the following beneficial effects:
[0023] (1) This invention screens out new markers (target genes DPP6, GHSR and ZIC1) for methylation as a diagnostic tool for cervical cancer and precancerous lesions, and uses the combination of any two of the target genes DPP6, GHSR and ZIC1 to diagnose cervical cancer, thereby improving clinical sensitivity by using dual-gene combination complementation.
[0024] (2) The present invention extracts DNA from urine samples for gene methylation testing, which is convenient and quick and greatly improves patient compliance.
[0025] (3) This invention uses a PCR reaction program to amplify gene methylation sequences, which can be automatically detected, has a high throughput, and provides objective results.
[0026] In addition to the objectives, features, and advantages described above, the present invention has other objectives, features, and advantages. The invention will now be described in further detail with reference to the figures. Attached Figure Description
[0027] The accompanying drawings, which form part of this application, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an undue limitation of the invention. In the drawings:
[0028] Figure 1(a) is a schematic diagram of the methylation rate of the DPP6_1m gene in the subjects diagnosed with CIN2+ in the experimental example of the present invention;
[0029] Figure 1(b) is a schematic diagram of the methylation rate of the DPP6_2m gene in the subjects diagnosed with CIN2+ in the experimental example of the present invention;
[0030] Figure 1(c) is a schematic diagram of the methylation rate of the GHSRm gene in the subjects diagnosed with CIN2+ in the experimental example of the present invention;
[0031] Figure 1(d) is a schematic diagram of the methylation rate of the GYPCm gene in the subjects diagnosed with CIN2+ in the experimental example of the present invention;
[0032] Figure 1(e) is a schematic diagram of the PAX1m gene methylation rate in subjects diagnosed with CIN2+ in the experimental example of this invention;
[0033] Figure 1(f) is a schematic diagram of the methylation rate of the ZIC1_1m gene in the subjects diagnosed with CIN2+ in the experimental example of the present invention;
[0034] Figure 1(g) is a schematic diagram of the methylation rate of the ZIC1_2m gene in the subjects diagnosed with CIN2+ in the experimental example of the present invention;
[0035] Figure 2(a) is a schematic diagram of the DPP6_1m gene methylation rate in subjects diagnosed with CIN3+ in the experimental example of the present invention;
[0036] Figure 2(b) is a schematic diagram of the methylation rate of the DPP6_2m gene in the subjects diagnosed with CIN3+ in the experimental example of the present invention;
[0037] Figure 2(c) is a schematic diagram of the methylation rate of the GHSRm gene in the subjects diagnosed with CIN3+ in the experimental example of the present invention;
[0038] Figure 2(d) is a schematic diagram of the methylation rate of the GYPCm gene in the subjects diagnosed with CIN3+ in the experimental example of the present invention;
[0039] Figure 2(e) is a schematic diagram of the PAX1m gene methylation rate in subjects diagnosed with CIN3+ in the experimental example of this invention;
[0040] Figure 2(f) is a schematic diagram of the methylation rate of the ZIC1_1m gene in the subjects diagnosed with CIN3+ in the experimental example of the present invention;
[0041] Figure 2(g) is a schematic diagram of the methylation rate of the ZIC1_2m gene in the subjects diagnosed with CIN3+ in the experimental example of this invention. Detailed Implementation
[0042] The following are specific embodiments of the present invention, which are described in conjunction with the accompanying drawings. However, the present invention is not limited to these embodiments.
[0043] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. The terminology used herein in the specification is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Example 1:
[0044] Three genes and five target regions were selected as biomarkers for cervical cancer detection in urine. The three genes are DPP6, GHSR, and ZIC1, with corresponding target regions of DPP6_1 (chr7:154001964-154002281), DPP6_2 (chr7:153748407-153748744), GHSR (chr3:172165506-172165751), and ZIC1_ 1 (chr3:147127500-147127769) and ZIC1_2 (chr3:147127988-147128286); where DPP6_1 represents the first target region in the DPP6 gene, DPP6_2 represents the second target region in the DPP6 gene, ZIC1_1 represents the first target region in the ZIC1 gene, and ZIC1_2 represents the second target region in the ZIC1 gene.
[0045] Primer and probe sequences were designed for the above-mentioned genes and their corresponding target regions, as shown in Table 1.
[0046] Table 1: Target regions, primer / probe sequences, and melting temperatures for gene methylation labeling
[0047]
[0048] Where: F represents the front primer, R represents the back primer, and P represents the probe.
[0049] Specifically, the DPP6_1 gene fragment is selected from hg19_dna range=chr7:154001964 - 1540022815'pad=0 3'pad=0 strand=+, and its original nucleic acid sequence is shown below:
[0050] ACGCGCTGTCTGGCGCGCCCTGCGTGGGGGCCGCAGGTTCAGACACCCGGGCGCGGCGCGGGGCCCTGATGGATGCGGTGACCGAGGCTGTGGCTGCGGGCGCGGCGTCTCCGCGGCAGTCGCTGCCTCCGCGGCCCCCTCCCCAGCCCCAGCCCCAGC CCCAGCCCCAGCCCCAGCCCCAGCCCCAGCCCCAGCCCCAGCCCCAGCCCGGCTGAGCGGGCGGCCGGAGCATGCGCCGTGGGCGCCGGGCCGGGAGGCGGGCGAGGAGGCAGCGCGCATCACTCGGGTCCCCTTCCTGCACCCAGCCGCCACTTGCCG
[0051] In the DPP6_1 nucleic acid sequence, under bisulfite conversion, methylated cytosine C remains unchanged, while unmethylated cytosine C is converted to uracil U. Uuracil U then becomes T during amplification. The converted nucleic acid sequence (B-DNA) is shown below:
[0052] ACGCGTTGTTTGGCGCGTTTTGCGTGGGGGTCGTAGGTTTAGATATTCGGGCGCGGCGCGGGGTTTTGATGGATGCGGTGATCGAGGTTGTGGTTGCGGGCGCGGCGTTTTCGCGGTAGTCGTTGTTTTCGCGGTTTTTTTTTTAGTTTTAGTTTTAGT TTTAGTTTTAGTTTTAGTTTTAGTTTTAGTTTTAGTTTTAGTTTTAGTTCGGTTGAGCGGGCGGTCGGAGTATGCGTCGTGGGCGTCGGGTCGGGAGGCGGGCGAGGAGGTAGCGCGTATTATTCGGGTTTTTTTTTTGTATTTAGTCGTTATTTGTCG
[0053] Primers and probes for the target region of DPP6_1 (chr7:154001964 - 154002281) were obtained based on the above nucleic acid sequence.
[0054] Specifically, the DPP6_2 gene fragment is selected from hg19_dna range=chr7:153748407 - 1537487445'pad=0 3'pad=0 strand=+, and its original nucleic acid sequence is shown below:
[0055] CCGGCCGGGAAGGGCTGGAAGGGGCGCGCAAGGAGGACGTGGGGACGAGACGAGAGACGCGTGCCCAGCAACTCCAGAAGGACGGAGAGGAGTGCAGAAGGGAGCCGGGGAGGACGCGGGAGGGCCGGGAGGGGAAGAGAAGCCAGGCCGGGCCTGGAGCGGAGGAG CGGAGCCCGCTGGTGCGGGTGTCCACACAGGGGCGCTGGAGCGCGCCTTCCTGCGGCTGGGCAGGAGGCAAGCCCGAGAGCGCGCGGCGAGTGGAGCCATGTCGCCCTCCCTCGCTCCGGCGGGCACAGTGAGGCGCAGGCTTTGGAAAAGTTGCGGGCAGCCGGAGA
[0056] In the DPP6_2 nucleic acid sequence, under bisulfite conversion, methylated cytosine C remains unchanged, while unmethylated cytosine C is converted to uracil U. Uuracil U then becomes T during amplification. The converted nucleic acid sequence (B-DNA) is shown below:
[0057] TCGGTCGGGAAGGGTTGGAAGGGGCGCGTAAGGAGGACGTGGGGACGACGAGAGAGACGCGTGTTTAGTAATTTTAGAAGGACGGAGAGGAGTGTAGAAGGGAGTCGGGGAGGACGCGGGAGGGTCGGGAGGGGAAGAGAAGTTAGGTCGGGTTTGGAGCGGAGGAG CGGAGTTCGTTGGTGCGGGTGTTTATATAGGGGCGTTGGAGCGCGTTTTTTTGCGGTTGGGTAGGAGGTAAGTTCGAGAGCGCGCGGCGAGTGGAGTTATGTCGTTTTTTTTCGTTTTCGGCGGGTATAGTGAGGCGTAGGTTTTGGAAAAGTTGCGGGTAGTCGGAGA
[0058] Primers and probes for the target region of DPP6_2 (chr7:153748407 - 153748744) were obtained based on the above nucleic acid sequence.
[0059] Specifically, the GHSR gene fragment is selected from hg19_dna range=chr3:172165506 - 172165751 5'pad=0 3'pad=0 strand=+, and its original nucleic acid sequence is shown below:
[0060] CTGTAGAGGACCGTGAGACAGAAGACAGGAAGGAAGAAGAAGATGCTGGACACCCACACCATGACCGTGAGCAGTCCAGAGCGCACCGCAAACTCGGTGGGGCGGCACTCGTTGGTGTCCCAAGGGTCGGTGCCGTTCTCGTGCTCCACCCCGACTAGCACGAAGATGGGCCCGGCGCTGCAGAAGGCCACGGCCCAGATGACGAAGATGACCAGCTTCACCCGCCCCTTGGTGACCACCACCTTG
[0061] In the GHSR nucleic acid sequence, methylated cytosine C remains unchanged under bisulfite conversion, while unmethylated cytosine C is converted to uracil U. Uuracil U then becomes T during amplification. The converted nucleic acid sequence (B-DNA) is shown below:
[0062] TTGTAGAGGATCGTGAGATAGAAGATAGGAAGGAAGAAGAAGATGTTGGATATTTATATTATGATCGTGAGTAGTTTAGAGCGTATCGTAAATTCGGTGGGGCGGTATTCGTTGGTGTTTTAA GGGTCGGTGTCGTTTTCGTGTTTTATTTCGATTAGTACGAAGATGGGTTCGGCGTTGTAGAAGGTTACGGTTTAGATGACGAAGATGATTAGTTTTATTCGTTTTTTGGTGATTATTATTTTG
[0063] Primers and probes for the target region of GHSR (chr3:172165506 - 172165751) were obtained based on the above nucleic acid sequence.
[0064] Specifically, the ZIC1_1 gene fragment is selected from hg19_dna range=chr3:147127500 - 1471277695'pad=0 3'pad=0 strand=+, and its original nucleic acid sequence is shown below:
[0065] TCCTCTATGCTACAAATCCAGGAGGAAGTTTTTTTTTAGGGGGCTGAGATGCTCCATGCCTTTCCCCGGGCAGCCTTGACGCGCGGCCCTCTCGGCAGAGACTGAGCGGCGAGAAAGTGCGAGCCGGGCCGGCAG AATCTGCCTGGCGGGCGCTGGAGCCTGCGTTACTCGCGGCCCGCAGCCGTCCGGCTACTTTGCGTTTGGCCCGGCCAGCGCCCGGGCGCGCCGCGCCATTGCCTGCAGGCTAGGACTTCGCGAGGTGGGTCGACT
[0066] Under bisulfite conversion, the methylated cytosine C in the ZIC1_1 nucleic acid sequence remains unchanged, while the unmethylated cytosine C is converted to uracil U. Uuracil U then converts to T during amplification. The converted nucleic acid sequence (B-DNA) is shown below:
[0067] TTTTTTATGTTATAAATTTAGGAGGAAGTTTTTTTTTAGGGGGTTGAGATGTTTTATGTTTTTTTTCGGGTAGTTTTGACGCGGTTTTTTCGGTAGAGATTGAGCGGCGAGAAAGTGCGAGTCGGGTCGGTAG AATTTGTTTGGCGGGCGTTGGAGTTTGCGTTATTCGCGGTTCGTAGTCGTTCGGTTATTTTGCGTTTGGTTCGGTTAGCGTTCGGGCGCGTCGCGTTATTGTTTGTAGGTTAGGATTTCGCGAGGTGGGTCGATT
[0068] Primers and probes for the target region ZIC1_1 (chr3:147127500 - 147127769) were obtained from the above nucleic acid sequence.
[0069] Specifically, the ZIC1_2 gene fragment > hg19_dna range=chr3:147127988 - 147128286 5'pad=0 3'pad=0 strand=+ has the following nucleic acid sequence:
[0070] AACGAGACGTGGGCCTGGGCATCAACCCGTTCGCCGACGGCATGGGCGCCTTCAAGCTCAACCCCAGTTCGCACGAGCTGGCTTCGGCCGGCCAGACGGCCTTCACGTCGCAGGCGCCAGGCTACGCGGCTGCTGCGGCCCTGGGCCAT CACCATCACCCGGGCCACGTCGGCTCCTATTCCAGCGCAGCCTTCAACTCCACGCGGGACTTTCTGTTCCGCAACCGGGGTTTTGGCGACGCGGCGGCGGCAGCCAGCGCACAGCACAGCCTCTTTGCTGCATCGGCCGGGGGCTTCGGG
[0071] Under bisulfite conversion, the methylated cytosine C in the ZIC1_2 nucleic acid sequence remains unchanged, while the unmethylated cytosine C is converted to uracil U. Uuracil U then converts to T during amplification. The converted nucleic acid sequence (B-DNA) is shown below:
[0072] AACGAGACGTGGGTTTGGGTATTAATTCGTTCGTCGACGGTATGGGCGTTTTTAAGTTTAATTTTAGTTCGTACGAGTTGGTTTCGGTCGGTTAGACGGTTTTTACGTCGTAGGCGTTAGGTTACGCGGTTGTTGCGGTTTTGGGTTAT TATTATTATTCGGGTTACGTCGGTTTTTATTTTAGCGTAGTTTTTAATTTTACCGGGATTTTTTGTTTCGTAATCGGGGTTTTGGCGACGGCGGCGGCGGTAGTTAGCGTATAGTATAGTTTTTTTGTTGTATCGGTCGGGGGTTTCGGG
[0073] Primers and probes for the target region of ZIC1_2 (chr3:147127988 - 147128286) were obtained based on the above nucleic acid sequence. Example 2:
[0074] I. Sample collection and pretreatment;
[0075] Collect at least 10 mL of urine from the subject and extract DNA from the urine using the Quick DNA Urine Kit (Zymo Research, Irvine, CA, US). Alternatively, use the DNA mini and blood mini kit (Kaiger, Germany) to extract DNA from urine sediment. Dissolve the DNA in 50 µL of elution buffer. Quantify the DNA concentration using NanoDrop; the minimum amount for gene methylation detection is 2 ng / µL. For fixed D gene methylation testing, use 100 ng or 200 ng of DNA and use the Hongya Gene Methylation Conversion Kit, following the instructions, to obtain converted nucleic acid (B-DNA) with a methylation conversion rate of over 99.6%.
[0076] II. Primer and probe synthesis;
[0077] Based on the nucleic acid sequences in Table 1, biosynthesis is performed by attaching fluorescent and quenching groups to the nucleic acid sequences during synthesis. The PCR instrument's fluorescence channels can be rationally designed, allowing probes in the same reaction system to have different fluorescent groups attached to their nucleic acid sequences. For example, probes for DPP6_1m, DPP6_2m, GHSRm, and GYPCm can be attached to different fluorescent groups, as can probes for PAX1m, ZIC1_1m, and ZIC1_2m. Thus, the detection of methylation of seven genes can be completed in two reaction systems.
[0078] III. Establishment of PCR reaction system;
[0079] Four target gene methylation markers (DPP6_1, DPP6_2, GHSR, and GYPC) and one internal reference gene (GAPDH(IC)) were used. Probes for three target gene methylation markers (PAX1, ZIC1_1, and ZIC1_2) and one internal reference gene (GAPDH(IC)) were attached with different fluorescent groups. Two PCR reaction systems were established using these seven gene methylation markers. The 25 μL system for the four target gene methylation markers consisted of: 2.5 μL of MIX for a 10×PCR reaction, 0.2–0.5 μL of DPP6_1 pre-primer, 0.2–0.5 μL of DPP6_1 post-primer, 0.2–0.5 μL of DPP6_1 probe, 0.2–0.5 μL of DPP6_2 pre-primer, 0.2–0.5 μL of DPP6_2 post-primer, 0.2–0.5 μL of DPP6_2 probe, and 0.2–0.5 μL of GHSR pre-primer. Add 0.2-0.5 μL of GHSR primer, 0.2-0.5 μL of GHSR probe, 0.2-0.5 μL of GYPC primer, 0.2-0.5 μL of GYPC primer, 0.2-0.5 μL of GYPC probe, 0.2-0.5 μL of GAPDH primer, 0.2-0.5 μL of GAPDH probe, and 2 μL of B-DNA. Add double-distilled water to a total volume of 25 μL. The 25 μL system for methylation labeling of the three target genes consisted of: 2.5 μL of MIX for a 10× PCR reaction, 0.2-0.5 μL of PAX1 pre-primer, 0.2-0.5 μL of PAX1 post-primer, 0.2-0.5 μL of PAX1 probe, 0.2-0.5 μL of ZIC1_1 pre-primer, 0.2-0.5 μL of ZIC1_1 post-primer, and 0.2-0.5 μL of ZIC1_1 probe. Add 0.5 μL of ZIC1_2 pre-primer, 0.2-0.5 μL of ZIC1_2 post-primer, 0.2-0.5 μL of ZIC1_2 probe, 0.2-0.5 μL of GAPDH pre-primer, 0.2-0.5 μL of GAPDH post-primer, 0.2-0.5 μL of GAPDH probe, and 2 μL of B-DNA. Then add double-distilled water to a total volume of 25 μL. It is worth noting that the seven methylation markers can be combined arbitrarily. The PCR reaction MIX is a PCR buffer containing four dNTPs, a thermostable DNA polymerase, magnesium ions, etc., while B-DNA is bisulfite-converted nucleic acid DNA, or externally synthesized nucleic acid methylated from the target gene or internal reference gene.
[0080] IV. Amplification reaction;
[0081] The prepared PCR reaction system is then used on a real-time PCR instrument. The corresponding PCR reaction program is set to amplify the gene methylation sequence. The PCR reaction program is as follows: 1. Pre-denaturation at 95℃ for 5-10 minutes to denature the DNA and activate DNA polymerase; 2. Denaturation at 90℃-95℃ for 15-30 seconds to separate the DNA double strands into single strands; 3. Annealing at 50℃-65℃ for 15-30 seconds to allow the primers to bind to the target DNA sequence; 4. Extension at 60℃-75℃ for 15-60 seconds, allowing DNA polymerase to synthesize new DNA strands along the template DNA strand. Steps 2, 3, and 4 are cycled 50 times, and fluorescence is recorded; 5. Terminate the PCR reaction and store the product at 4℃ for analysis.
[0082] V. Interpretation Criteria;
[0083] 1. The criteria for interpreting gene methylation are as follows:
[0084] Gene (GENE) methylation is denoted as GENEm. The result of single-gene methylation detection is ΔCt, calculated using the formula: ΔCt = Ct(GENE) - Ct(IC). The interpretation of single-gene methylation results is as follows: ΔCt(GENE) ≤ t(5-15) is positive; ΔCt(GENE) > k is negative.
[0085] 2. The interpretation of the combined detection of dual-gene methylation is as follows:
[0086] To improve sensitivity, the interpretation criteria for the combined detection of dual gene methylation are as follows: a positive result is interpreted as a positive result if methylation of any one gene is positive, and a negative result is interpreted as a negative result if both genes are negative.
[0087] Experimental example:
[0088] Urine samples were collected from 655 patients at the hospital's gynecology outpatient clinic who were HR-HPV positive or had abnormal cytology for methylation testing. Colposcopy and biopsy confirmed cervicitis in 186 cases, CIN1 in 356 cases, CIN2 in 57 cases, CIN3 in 49 cases, and cervical cancer in 7 cases. The areas under the receiver operating characteristic (ROC) curves (AUC) for DPP6_1m, DPP6_2m, GHSRm, GYPCm, PAX1m, ZIC1_1m, and ZIC1_2m in diagnosing CIN2+ were 0.796, 0.793, 0.757, 0.777, 0.766, 0.753, and 0.762, respectively (Figures 1(a) to 1(g)). The areas under the receiver operating characteristic (ROC) curves (AUC) for DPP6_1m, DPP6_2m, GHSRm, GYPCm, PAX1m, ZIC1_1m, and ZIC1_2m in diagnosing CIN3+ were 0.905, 0.849, 0.885, 0.904, 0.909, 0.870, and 0.894, respectively (see Figures 2(a) to 2(g)). Based on the principle of maximizing the Youden index for diagnosing CIN2+, the optimal cutoff values were selected as 14.68, 14.92, 14.60, 13.83, 14.49, 14.55, and 14.50, respectively. The positive rates of DPP6_1m, DPP6_2m, GHSRm, GYPCm, PAX1m, ZIC1_1m, and ZIC1_2m increased with the degree of cervical lesions (cervicitis, CIN1, CIN2, CIN3, cervical cancer), and the positive rate of all of them was 100% in cervical cancer. See Table 2 for details.
[0089] Table 2 Positive rates of gene methylation in different cervical lesions
[0090]
[0091] The single-gene diagnoses of CIN2+ by DPP6_1m, DPP6_2m, GHSRm, GYPCm, PAX1m, ZIC1_1m, and ZIC1_2m all have specificities exceeding 80%, but their sensitivities are relatively low. Their positive predictive values are all above 90%. The single-gene diagnoses of CIN3+ by DPP6_1m, GHSRm, GYPCm, PAX1m, and ZIC1_2m have sensitivities exceeding 80%, and their negative predictive values are all above 95%. Single-gene diagnoses of high-grade precancerous lesions of the cervix are accurate in providing negative predictions, ensuring that patients with negative results have a very low probability of developing CIN2+ (see Table 3).
[0092] Table 3. Clinical performance of monogenic methylation in diagnosing CIN2+ / CIN3+
[0093]
[0094] The combined use of two genes for diagnosis improved clinical sensitivity and negative predictive value, especially for the diagnosis of CIN3+, with sensitivity exceeding 90% and negative predictive value exceeding 99%. It also maintained high specificity, exceeding 75% (see Table 4).
[0095] Table 4. Clinical performance of combined dual-gene methylation detection in diagnosing CIN2+ / CIN3+
[0096]
[0097] Urine samples are used for cervical cancer gene methylation testing. Sample collection is convenient, and the sensitivity and negative predictive value for diagnosing CIN3+ are high, making it suitable for large-scale screening.
[0098] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.
Claims
1. A primer-probe combination for detecting methylation of cervical cancer genes, characterized in that: It comprises the nucleic acid sequence shown in 1)-2) below: 1) PCR primers and probes for detecting methylation of the DPP6 gene, including a front primer as shown in SEQ ID NO.1, a rear primer as shown in SEQ ID NO.2, and a fluorescent probe as shown in SEQ ID NO.3; and 2) PCR primers and probes for detecting methylation of the GHSR gene, including a front primer as shown in SEQ ID NO.7, a rear primer as shown in SEQ ID NO.8, and a fluorescent probe as shown in SEQ ID NO.
9.
2. Use of the primer-probe combination for methylation of cervical cancer genes as described in claim 1 in the preparation of a cervical cancer detection kit.
3. The use according to claim 2, characterized in that: The sample to be tested in the detection kit is set as a urine sample.
